Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adverse Effects
Conditions
Adverse Effects
Trial Timeline
Sep 1, 2011 → Feb 1, 2014
NCT ID
NCT01764126About Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine
Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine is a phase 1 stage product being developed by Sanofi for Adverse Effects. The current trial status is completed. This product is registered under clinical trial identifier NCT01764126. Target conditions include Adverse Effects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01764126 | Phase 1 | Completed |
Competing Products
7 competing products in Adverse Effects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABT-143 + ABT-335 and rosuvastatin | AstraZeneca | Phase 1 | 33 |
| Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD1222 | AstraZeneca | Pre-clinical | 23 |
| ABT-143 + ABT-335 + Rosuvastatin | AstraZeneca | Phase 1 | 33 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 69 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 77 |